On August 14, HENGRUI PHARMA fell 3.19% in regular trading, trading at 53.3 HKD/share, with turnover of approximately 49.84 million HKD.

The decline comes ahead of the company's interim results announcement scheduled for August 19. Market institutions have flagged a significant gap in quarterly revenue forecasts, with cautious views dominating. The core concern centers on whether innovative drug volume growth can sufficiently offset adverse impacts from pricing pressure and elevated expense ratios, with net margin sustainability under scrutiny.

Additionally, recent institutional positioning adjustments have added selling pressure. Wellington Management sold approximately 508,300 shares at an average price of 58.36 HKD, reducing its stake to 6.91%. Citigroup's H-share long position also declined from 5.06% to 4.11% as of August 3.

Broader sector weakness compounded the pressure, with the Pharmaceuticals sector declining across the board. Among peers, CSPC PHARMA fell 1.75%, HANSOH PHARMA dropped 2.19%, SBP GROUP declined 1.54%, ASYMCHEM lost 0.67%, and LUYE PHARMA slid 2.13%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)